In:
Current Opinion in Oncology, Ovid Technologies (Wolters Kluwer Health), Vol. 34, No. 5 ( 2022-09), p. 466-472
Abstract:
Studies on treatment options for patients with locally advanced vulvar cancer (LAVC) are scarce, and high-level evidence for a primary treatment choice is lacking. Furthermore, current treatment options are associated with extensive morbidity and high complication rates. More effective treatment options are urgently needed. This review describes current treatment possibilities, focusing on literature regarding neoadjuvant chemotherapy (NACT) followed by surgery. Recent findings Although data are heterogeneous and limited, NACT followed by surgery might be an effective and well tolerated treatment alternative associated with lower morbidity compared with current treatment options, such as excenterative surgery or definitive chemoradiation. Summary Up until now, several studies describe an overall response rate of 40–86%. Surgery turned out to be possible in 40–90% of the LAVC patients who received NACT. Prospective studies on the efficacy and safety of NACT followed by surgery with a homogeneous chemotherapy regimen are urgently awaited. NACT should, at this point, still be considered investigational.
Type of Medium:
Online Resource
ISSN:
1040-8746
,
1531-703X
DOI:
10.1097/CCO.0000000000000861
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2022
detail.hit.zdb_id:
2026986-9
Bookmarklink